G J Laurent
Overview
Explore the profile of G J Laurent including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
133
Citations
2963
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maher T, Wells A, Laurent G
Eur Respir J
. 2007 Nov;
30(5):835-9.
PMID: 17978154
Idiopathic pulmonary fibrosis (IPF) is a devastating condition that carries a prognosis worse than that of many cancers. A recent classification of the idiopathic interstitial pneumonias has redefined the diagnostic...
2.
Laurent G, Chambers R, Hill M, McAnulty R
Biochem Soc Trans
. 2007 Jul;
35(Pt 4):647-51.
PMID: 17635112
Fibroblasts are multifunctional cells that are responsible for matrix homoeostasis, continuously synthesizing and degrading a diverse group of extracellular molecules and their receptors. Rates of turnover of matrix molecules and...
3.
Degiorgio-Miller A, Treharne L, McAnulty R, Coleridge Smith P, Laurent G, Herrick S
Br J Dermatol
. 2005 Feb;
152(2):242-9.
PMID: 15727634
Background: Lipodermatosclerosis (LDS) is characterized by a hardening and hyperpigmentation of lower leg skin as a consequence of chronic venous insufficiency. The degree of skin hardening or fibrosis associated with...
4.
5.
Hill M, Briggs L, Montano M, Estrada A, Laurent G, Selman M, et al.
Thorax
. 2004 Jun;
59(7):586-90.
PMID: 15223866
Background: Tissue inhibitors of metalloproteinases (TIMPs) play a major role in extracellular matrix turnover in the lung. However, in chronic lung disorders such as idiopathic pulmonary fibrosis (IPF) and pigeon...
6.
Atzori L, Chua F, Dunsmore S, Willis D, Barbarisi M, McAnulty R, et al.
Thorax
. 2004 Feb;
59(3):217-23.
PMID: 14985557
Background: Pulmonary fibrosis is associated with a poor prognosis. The pathogenesis of fibrotic lung disorders remains unclear, but the extent of tissue damage due to the persistent presence of oxidants...
7.
Jenkins R, McAnulty R, Hart S, Laurent G
Monaldi Arch Chest Dis
. 2003 Oct;
59(1):17-24.
PMID: 14533278
Pulmonary gene therapy offers the hope of treatment for conditions such as cystic fibrosis, lung cancer, pulmonary fibrosis and acute respiratory distress syndrome for which current therapy is inadequate. Although...
8.
Dik W, McAnulty R, Versnel M, Naber B, Zimmermann L, Laurent G, et al.
Thorax
. 2003 Aug;
58(9):765-71.
PMID: 12947134
Background: Corticosteroids are routinely used in patients with pulmonary fibrosis. The timing for initiation of treatment is likely to be crucial for corticosteroids to exert an antifibrotic effect. Experimental studies...
9.
Jenkins R, Meng Q, Hodges R, Lee L, Bottoms S, Laurent G, et al.
Gene Ther
. 2003 May;
10(12):1026-34.
PMID: 12776160
There is currently an urgent need to develop efficient gene-delivery systems for the lung that are free of inflammatory effects. The LID vector is a synthetic gene delivery system, comprised...
10.
Simler N, Howell D, Marshall R, Goldsack N, Hasleton P, Laurent G, et al.
Eur Respir J
. 2002 Jul;
19(6):1124-7.
PMID: 12108867
Pulmonary fibrosis is characterized by excessive deposition of extracellular matrix proteins within the pulmonary interstitium. The new macrolide immunosuppressant SDZ RAD, a rapamycin analogue, inhibits growth-factor dependent proliferation of mesenchymal...